Pathway targets to explore in the treatment of non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 3, Issue 11, 2008, Pages 1342-1352

  Weiss, Glen J ^a,b,c   Kingsley, Chris ^a  

^a Scottsdale Clinical Research Institute   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c NONE   (United States)

Author keywords

Gene expression profiling; In silico; Non small cell lung cancer; Pathway analysis

Indexed keywords

DASATINIB; EFALIZUMAB; IMATINIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NATALIZUMAB; PLERIXAFOR; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; COMPUTER MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE MAPPING; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; SURVIVAL RATE; ADENOCARCINOMA; DNA MICROARRAY; DRUG EFFECT; GENETICS; LUNG; LUNG TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; GENE EXPRESSION PROFILING; HUMANS; LUNG; LUNG NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 58949092362     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181898774     Document Type: Article

References (33)

1. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer [erratum in N Engl J Med 2007;356:318]. N Engl J Med 2006;355:2542-2550.
2. Manegold C, von Pawel J, Zatloukal P, et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cispla-tin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 2007;25:LBA7514.
3. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
4. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
5. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung cancer). Lancet 2005;366: 1527-1537.
6. Jemal A, Siegel R, Ward E, et al. cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
7. Lau SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 2007;25:5562-5569.
8. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-569.
9. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-357.
10. Hubbell E, Liu WM, Mei R. Robust estimators for expression analysis. Bioinformatics 2002;18:1585-1592.
11. Coombes KR, Wang J, Baggerly KA. Microarrays: retracing steps. Nat Med 2007;13:1276-1277, author reply 1277-1278.
12. Geo Datasets GSE8894 record: prediction of Recurrence-Free Survival in Postoperative NSCLC Patients - a Useful Prospective Clinical Practice.
13. Wu Z, Irizarry RA, Gentleman R, et al. A Model-Based Background Adjustment for Oligonucleotide Expression Arrays. J Am Stat Assoc 2004;99:909-917.
14. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98:13790-13795.
15. Su LJ, Chang CW, Wu YC, et al. Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. BMC Genomics 2007;1:140.
16. Geo Datasets GSE6044 record: Genetic programming and gene expression profiling for molecular discrimination and characterization of lung cancers.
17. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-824.
18. Expo. .
19. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-264.
20. Ingenuity Pathway Analysis, .
21. Bioconductor open source for bioinformatics, .
22. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodological) 1995;57:289-300.
23. Huang CH, Williamson S, van Veldhuizen PJ, et al. Phase II trial of imatinib (I) and docetaxel (D) in recurrent non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25: Abstract 18132.
24. Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005;11:6924-6932.
25. Choong NW, Mauer AM, Hoffman PC, et al. Phase II trial of temozo-lomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. J Thorac Oncol 2006;1:245-251.
26. Cancer Trials, .
27. Ramlau R, Zatloukal P, Jassem J, et al. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/ vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. J Clin Oncol 2008;26:1886-1892.
28. Blumenschein GR Jr, Khuri FR, von Pawel J, et al. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J Clin Oncol 2008;26:1879-1885.
29. Zhang J, Kalyankrishna S, Wislez M, et al. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 2007;170:366-376.
30. Li JP. Heparin, heparan sulfate and heparanase in cancer: remedy for metastasis? Anticancer Agents Med Chem 2008;8:64-76.
31. Lee AY. The effects of low molecular weight heparins on venous thromboembolism and survival in patients with cancer. Thromb Res 2007;120:S121-S127.
32. Pirker R, Szczesna A, von Pawel J, et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/ vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008;26:Abstract 3.
33. von Eyben FE. Epidermal growth factor receptor inhibition and non-small cell lung cancer. Crit Rev Clin Lab Sci 2006;43:291-323.